CS
ALGS icon

Credit Suisse’s Aligos Therapeutics ALGS Stock Holding History

Credit Suisse’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Hold
0
– – – 4021
2022
Q2 		– Sell
-574
Closed -$19.5K – 3894
2022
Q1 		$31K Buy
574
+36
+7% +$2.88K ﹤0.01% 3532
2021
Q4 		$159K Sell
538
-7
-1% -$2.55K ﹤0.01% 4328
2021
Q3 		$211K Buy
+545
New +$216K ﹤0.01% 4213

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse's ALGS Position: Q3 2022 in Review

Credit Suisse held its Aligos Therapeutics (ALGS) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4021.

Credit Suisse first reported a position in ALGS in Q3 2021 and has held it in 3 quarters since. The position peaked at $211K in Q3 2021. 52 funds tracked by Wall St. Rank hold ALGS as of Q3 2022.

  • Credit Suisse held 0 shares of Aligos Therapeutics worth $0 as of Q3 2022.
  • Credit Suisse left its Aligos Therapeutics share count unchanged in Q3 2022.
  • Aligos Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4021 holding.
  • Credit Suisse first reported a position in Aligos Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Credit Suisse's Aligos Therapeutics position peaked at $211K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.